KRAS and neoplasm: Tumours treated with αEGFR-mAB-P/KRAS-siRNA/P nanostructures had reduced proliferation rates compared to PBS or control-treated tumours as determined by detection of the proliferation marker Ki67 by immunofluorescence (Supplementary Fig. 7) and higher apoptosis rates as determined by TUNEL staining (Supplementary Fig. 7).